UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
12b-25
| |
NOTIFICATION
OF LATE FILING |
SEC
FILE NUMBER |
| 001-41880 |
| |
|
|
| |
|
CUSIP
NUMBER |
| |
|
G01341109 |
| (Check One):
|
☒ Form
10-K ☐ Form 20-F ☐ Form 11-K ☐ Form 10-Q ☐ Form 10-D ☐ Form N-CEN ☐ Form
N-CSR |
For
Period Ended: December 31, 2025
| |
☐ |
Transition Report on Form
10-K |
| |
☐ |
Transition Report on Form
20-F |
| |
☐ |
Transition Report on Form
11-K |
| |
☐ |
Transition Report on Form
10-Q |
For
the Transition Period Ended: _______________
Read
Instruction (on back page) Before Preparing Form. Please Print or Type.
Nothing
in this form shall be construed to imply that the Commission has verified any
information
contained herein.
If
the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates:
PART
I – REGISTRANT INFORMATION
Aimei
Health Technology Co., Ltd
Full
Name of Registrant
Former
Name if Applicable
10
East 53rd Street, Suite 3001
Address
of Principal Executive Office (Street and Number)
New
York, NY 10022
City,
State and Zip Code
PART
II – RULES 12b-25(b) AND (c)
If
the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b),
the following should be completed. (Check box if appropriate)
| |
(a) |
The reasons described in
reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense; |
| ☒ |
(b) |
The
subject annual report, semi-annual report, transition report on Form10-K, Form 20-F, Form 11-K, Form N-CEN or Form N-CSR, or portion
thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report
or transition report on Form 10-Q or subject distribution report on Form 10-D, or portion thereof, will be filed on or before the
fifth calendar day following the prescribed due date; and |
| |
(c) |
The accountant’s
statement or other exhibit required by Rule 12b-25(c) has been attached if applicable. |
PART
III – NARRATIVE
State
below in reasonable detail why Forms 10-K, 20-F, 11-K, 10-Q, 10-D, N-CEN, N-CSR, or the transition report or portion thereof, could not
be filed within the prescribed time period.
We
could not timely file our Annual Report on Form 10-K for the fiscal year ended December 31, 2025 because the review of the annual report
on Form 10-K could not be completed in a timely fashion prior to the due date of the report.
PART
IV – OTHER INFORMATION
| (1) |
Name and telephone
number of person to contact in regard to this notification |
| Junheng
Xie |
|
+86 |
|
13758131392 |
| (Name) |
|
(Area
Code) |
|
(Telephone
Number) |
| (2) |
Have
all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment
Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s)
been filed? If answer is no, identify report(s).
|
☒
Yes ☐ No |
| |
|
|
| (3) |
Is
it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be
reflected by the earnings statements to be included in the subject report or portion thereof?
|
☐
Yes ☒ No |
If
so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why
a reasonable estimate of the results cannot be made.
Aimei
Health Technology Co., Ltd
(Name
of Registrant as Specified in Charter)
has
caused this notification to be signed on its behalf by the undersigned hereunto duly authorized.
| Date: April
1, 2026 |
By: |
/s/
Junheng Xie |
| |
Name: |
Junheng
Xie |
| |
Title: |
Chief Executive Officer and Director |
INSTRUCTION:
The form may be signed by an executive officer of the registrant or by any other duly authorized representative. The name and title of
the person signing the form shall be typed or printed beneath the signature. If the statement is signed on behalf of the registrant by
an authorized representative (other than an executive officer), evidence of the representative’s authority to sign on behalf of
the registrant shall be filed with the form.
| |
ATTENTION |
|
| |
|
| Intentional
misstatements or omissions of fact constitute Federal Criminal Violations (See 18 U.S.C. 1001). |
